1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
JUNE 30, 2001
-------------
Date of Report
(Date of earliest event reported)
HUMAN GENOME SCIENCES, INC.
---------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-022962 22-3178468
------------------------------- ------------------------ --------------------------------
(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)
Incorporation)
9410 KEY WEST AVENUE, ROCKVILLE, MARYLAND 20850-3338
-----------------------------------------------------
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (301) 309-8504
--------------
(Former Name or Former Address, if Changed Since Last Report)
2
ITEM 5. OTHER EVENTS.
On July 2, 2001, Human Genome Sciences announced that the exclusivity
period for its human gene therapeutic consortium expired on June 30, 2001, a
period described as the initial research term. None of the consortium members
chose to extend the initial research term.
Upon expiration of the initial research term, work already initiated by
the members can continue if evidence of continued diligence is provided, but no
new use of Human Genome Sciences' technology is permitted by the members.
Collectively, the members are actively pursuing approximately 430 programs
involving approximately 280 different genes for the creation of small molecule
and antibody drugs. They also are developing approximately 30 therapeutic
protein drugs. Human Genome Sciences can provide no assurance that any of these
programs will result in approved drugs, or if approved, that any of the drugs
can be successfully commercialized. If any of these programs result in drugs
that are commercialized, Human Genome Sciences will be entitled to certain
milestone and royalty payments. In addition, for drugs developed by
GlaxoSmithKline, Human Genome Sciences will be entitled to certain co-promotion
rights.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HUMAN GENOME SCIENCES, INC.
Date: July 6, 2001 By: /s/ James H. Davis, Ph.D.
-----------------------------------------
James H. Davis, Ph.D.
Senior Vice President and General
Counsel